Back to top
more

National Vision (EYE)

(Delayed Data from NSDQ)

$17.88 USD

17.88
768,041

+0.01 (0.06%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $17.89 +0.01 (0.06%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 44% (140 out of 252)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

National Vision (EYE) Q1 Earnings Top Estimates

by Zacks Equity Research

National Vision (EYE) delivered earnings and revenue surprises of 22.22% and 4.07%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Owens & Minor (OMI) Beats Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Owens & Minor (OMI) delivered earnings and revenue surprises of 24.68% and 3.55%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

National Vision (EYE) Up 23.6% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

National Vision (EYE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

National Vision (EYE) Hurt by Rising Costs, Vendor Dependency

by Zacks Equity Research

High dependence on a limited number of suppliers exposes National Vision (EYE) to supplier concentration risk.

National Vision (EYE) Q4 Earnings Top Estimates, Margins Down

by Zacks Equity Research

Strength in America's Best and Eyeglass World brands drove National Vision's (EYE) performance in the fourth quarter of 2021.

National Vision (EYE) Tops Q4 Earnings and Revenue Estimates

by Zacks Equity Research

National Vision (EYE) delivered earnings and revenue surprises of 750% and 4.43%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Zynex Inc. (ZYXI) Q4 Earnings Surpass Estimates

by Zacks Equity Research

Zynex Inc. (ZYXI) delivered earnings and revenue surprises of 21.05% and 1.69%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate National Vision (EYE) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

National Vision (EYE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Meridian Bioscience (VIVO) Q1 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Meridian Bioscience (VIVO) delivered earnings and revenue surprises of 40% and 19.78%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Here's Why You Should Hold on to National Vision (EYE) for Now

by Zacks Equity Research

Investors are optimistic about National Vision (EYE), given new store growth for America's Best and Eyeglass World brands.

Abbott (ABT) Scales to a 52-Week High: What's Driving It?

by Zacks Equity Research

Strong performance by the Diabetes Care and Diagnostics businesses is driving the top line for Abbott (ABT).

Cardiovascular Systems (CSII) Business Down on COVID Resurgence

by Zacks Equity Research

According to Cardiovascular Systems (CSII), the resurgence of COVID-19 and the related staffing shortages are disrupting referral patterns and having the largest impact on elective procedures.

Walgreens (WBA), VillageMD Plan to Expand Into Tampa, Florida

by Zacks Equity Research

Walgreens (WBA), VillageMD to open 20 new Village Medical at Walgreens primary care practices in the Tampa area to improve access to overall care for patients with chronic conditions.

Here's Why You Should Hold on to Teleflex (TFX) Stock for Now

by Zacks Equity Research

Investors are optimistic about Teleflex (TFX) owing to better-than-anticipated results in the third quarter and strength in the Vascular business.

Here's Why You Should Add LabCorp (LH) to Your Portfolio Now

by Zacks Equity Research

Investors are optimistic about LabCorp (LH) backed by consistent recovery across its businesses and raised 2021 guidance.

Omnicell (OMCL) Inks New Deal to Manage Controlled Substances

by Zacks Equity Research

Omnicell (OMCL), Fresenius Kabi collaborate to offer safe and efficient dispensing of controlled substances across hospitals and health systems in the United States.

National Vision (EYE) Q3 Earnings Top Estimates, Margins Fall

by Zacks Equity Research

Strength in America's Best and Eyeglass World brands drove National Vision's (EYE) revenues in the third quarter of 2021.

National Vision (EYE) Q3 Earnings and Revenues Top Estimates

by Zacks Equity Research

National Vision (EYE) delivered earnings and revenue surprises of 52.00% and 0.84%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

National Vision (EYE) Hits Fresh High: Is There Still Room to Run?

by Zacks Equity Research

National Vision (EYE) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Earnings Preview: National Vision (EYE) Q3 Earnings Expected to Decline

by Zacks Equity Research

National Vision (EYE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Here's Why You Should Hold on to Walgreens Boots (WBA) for Now

by Zacks Equity Research

Investors are optimistic about Walgreens Boots (WBA) given its better-than-expected fourth-quarter fiscal 2021 results and strategic alliances.

Here's Why You Should Hold on to Hill-Rom (HRC) for Now

by Zacks Equity Research

Investors are optimistic about Hill-Rom (HRC) owing to strategic buyouts and continued expansion efforts in the digital health space.

3 Reasons to Hold on to Boston Scientific (BSX) Stock For Now

by Zacks Equity Research

Investors are optimistic about Boston Scientific (BSX) given its recent acquisitions and strength in the structural heart business.

Walgreens (WBA) to Make Additional Investment in VillageMD

by Zacks Equity Research

Walgreens (WBA) announced a $5.2-billion investment in VillageMD to bolster its strategic position in delivering value-based primary care.